Global clotting assays - monitoring the effect of by-passing agents in haemophilia patients with inhibitors

Open access


The development of FVIII/FIX inhibitor alloantibodies represents a severe complication requiring specific laboratory evaluation for establishing a life-saving therapy regimen. Our preliminary study aimed at elaborating a laboratory strategy for monitoring the effectiveness of Activated Prothrombin Complex Concentrate (APCC) and recombinant activated factor VII (rFVIIa) in haemophiliacs with inhibitors, by checking the reliability and clinical value of three complementary assays: clotting-time based coagulometry, thrombelastography (TEG) and thrombin generation assay (TGA). The investigations were performed on 7 patients with severe haemophilia A with high titer inhibitors treated for 12 episodes of severe bleedings, 5 of them for surgical interventions. After the administration of bypassing agents (BPAs) the clotting-time based assay brought changes only on prothrombin (p<0.01), potentially signaling a thrombotic risk, without any impact on the global hemostasis. TEG displayed prompt significant improvement only after rFVIIa (90μg/kg). TGA revealed significantly improved values for peak and velocity index, time to peak and start tail after both BPAs. Despite some disparities between biological hemostatic phenotype and clinical response to therapy, we concluded that TEG and TGA are the only current exploratory assays, expressing the quality of haemostatic control, representing a real support for a personalized, adapted therapy in hemophilia with inhibitors.

1. Tripodi A. The Long-Awaited Whole-Blood Thrombin Generation Test. Clin Chem. 2012;58(8):1173-5. DOI: 10.1373/clinchem.2012.189266

2. Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, et al. The Calibrated Automated Thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb. 2002;32:249-53. DOI: 10.1159/000073575

3. Marcus D Lance. A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis. Lance Thrombosis J. 2015;13:1. DOI: 10.1186/1477-9560-13-1

4. Kern A, Varnai K, Vasarhelyi B. Thrombin generation assays and their clinical application. Orv Hetil. 2014; 155 (22):851-7. DOI: 10.1556/OH.2014.29899

5. Young G, Sorensen B, Dargaud Y, Negrier C, Brummel- Ziedins K, Nigel S, et al. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood. 2013; 121 (11):1944-50. DOI: 10.1182/ blood-2012-08-378935

6. Mancuso ME, Fasulo MR. Thrombin Generation Assay as a Laboratory Monitoring Tool during Bypassing Therapy in Patients with Hemophilia and Inhibitors. Semin Thromb Haemost. 2016;42:30-5.

7. Mancuso ME, Chantaragkul V, Clerici M. Low thrombin generation during major orthopedic surgery fails to predict bleeding risk in inhibitor patients treated with bypassing agents. Haemophilia. 2016;22(4):292-30. DOI: 10.1111/hae.12939

8. Turecek PL, Varadi K, Keil B, Negrier C, Berntorp E, Astermark J, et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb. 2003;33 (1):16-22. DOI: 10.1159/000071637

9. Dargaud Y, Lienhart A, Meunier S, Hequet O, Chavanne H, Chamouard V, et al. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia.2005;11(5):552-8. DOI: 10.1111/j.1365-2516.2005.01141.x

10. 1Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood. 2010; 116 (25):5734-7. DOI: 10.1182/blood-2010-06-291906

11. Mancuso ME, Chantarangkul V, Clerici M. Thrombin generation assay in hemophilic patients with or without inhibitors undergoing orthopedic surgery. Haemophilia. 2014; 20 (3):10.

12. Instrumentation laboratory ACL ELITE* / ELITE PRO System. Reagents, controls and calibrators package’s inserts. PN 722277 Rev. BB (November 2010) Beckman Coulter, Inc.

13. Shima M, Matsumoto T, Ogiwara K New assays for monitoring haemophilia treatment. Haemophilia. 2008;3:83-92. DOI: 10.1111/j.1365-2516.2008.01737.x

14. Ninivaggi M, Apitz-Castro R, Dargaud Y, de Laat B, Coenraad Hemker H, Lindhout T, et al. Whole- Blood Thrombin Generation Monitored with a Calibrated Automated Thrombogram-Based Assay. Clin Chem. 2012; 58 (8):1252-9. DOI: 10.1373/ clinchem.2012.184077

15. Mahlangu J, Kuliczkowski K, Karim FA, Stasyshyn O, Kosinova MV, Lepatan LM, et al. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood. 2016; 128 (5): 630-637. DOI: 10.1182/blood-2016-01-687434

16. Sorensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia. 2005; 11 (1):1-6. DOI: 10.1111/j.1365-2516.2005.01156.x

17. Négrier C, Gomperts ED, Oldenburg J. The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor. Haemophilia. 2006;12:4-13. DOI: 10.1111/j.1365-2516.2006.01379.x

18. Dargaud Y, Prevost C, Lienhart A, Bordet JC, Negrier C. Evaluation of the overall haemostatic effect of recombinant factor VIIa by measuring thrombin generation and stability of fibrin clots. Haemophilia. 2011;17:957-61. DOI: 10.1111/j.1365-2516.2011.02526.x

19. Vila V, Aznar JA, Moret A, Marco A, Navarro S, Vila C, et al. Assessement of the thrombin generation assay in haemophilia: comparative study between fresh and frozen platelet-rich plasma. Haemophilia. 2013;19:318-21. DOI: 10.1111/hae.12044

20. Perrin J, Depasse P, Lecompte T. Large external quality assessment survey on thrombin generation with CAT: further evidence for the usefulness of normalization with an external reference plasma. Thromb Res. 2016;135(1):125-130.

Revista Romana de Medicina de Laborator

Romanian Journal of Laboratory Medicine

Journal Information

IMPACT FACTOR 2018: 0,800
5-year IMPACT FACTOR: 0,655

CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2018: 0.194
Source Normalized Impact per Paper (SNIP) 2018: 0.306


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 222 157 10
PDF Downloads 88 71 5